Global surgical site infection market is forecasted to reach $5.9 billion by 2023. The market growth can be attributed to the development of technologically advanced products and growing geriatric population. Furthermore, increasing number of surgical procedures and rising incidence of SSIs are boosting the market growth.
Request for report sample at: http://bit.ly/2woqEd8
Antibiotic prophylaxis products generated the largest revenue in the surgical site infection market in 2017. In most cases, patients’ sensitivity to certain drugs creates the need for specific antibiotics, which, in turn, adds to the treatment cost. Owing to this factor, antibiotic prophylaxis products continue to be in high demand in the market. However, the fastest growth in the market during the forecast period is expected from the antiseptic and disinfectant product category, with a CAGR of 7.4%.
Hospitals have been contributing the largest revenue to the surgical site infection market, owing to increase in the number of surgeries and a significant increase in the number of hospitals on a global level, which is further leading to the increased use of products that help prevent surgical site infections.
Browse full report at: http://bit.ly/2x5cvRr
During the forecast period, the surgical site infection market is expected to witness the fastest growth in APAC, at a CAGR of 7.7%. The APAC surgical site infection market is also expected to reach $1,492.8 million by 2023. The market growth in APAC is mainly driven by growing geriatric population, rising incidence of SSIs, increasing adoption of technologically advanced products, and improving healthcare infrastructure.
Some of the key players operating in the surgical site infection market are 3M Company, STERIS plc, Stryker Corporation, Medtronic plc, Prescient Surgical Inc., Covalon Technologies Ltd., Surgical Site Infection Prevention LLC, HARTMANN GROUP, B. Braun Melsungen AG, and Becton, Dickinson and Company.
Source: P&S Intelligence